GlassScriptPhysician profile
Ann T Holmes
NPI 1225267966
$11,671.13
in general payments reported to CMS, 2019-2025
56 companies · $1,477 in 2025
The $1,477 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,451 · 2020: $1,399 · 2021: $1,445 · 2022: $1,521 · 2023: $1,984 · 2024: $2,395 · 2025: $1,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,855.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,106.74 | 2019-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,457.79 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,359.28 | 2019-2025 | |
| Novo Nordisk INC | $797.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $608.71 | 2019-2025 | |
| Lilly USA, LLC | $558.77 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $407.45 | 2021-2023 | Trintellix |
| Axsome Therapeutics, INC. | $397.63 | 2023-2025 | Auvelity |
| Glaxosmithkline, LLC. | $301.46 | 2019-2025 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.42 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $204.95 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $203.93 | 2023-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $179.19 | 2019-2025 | Veozah |
| Biohaven Pharmaceuticals, INC. | $164.11 | 2020-2021 | |
| Shield Therapeutics INC | $156.25 | 2023-2025 | Accrufer |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.